読み込み中
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
前日終値
$5.61
−$0.13 · -2.26%
時間外
$5.61
$0.00 · 0.00%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
日中レンジ
現在 $5.61
52週レンジ
現在 $5.61
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
31
割高
センチメント
58
まちまち
リスク
77
高リスク
モメンタム
47
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
日中レンジ
現在 $5.61
52週レンジ
現在 $5.61
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 2499万 USD | 973万 USD |
| 売上原価 | 638.1万 USD | — | — | — | — |
| 粗利益 | −638.1万 USD | — | — | 2499万 USD | 973万 USD |
| 研究開発 | 9912.7万 USD | 9932.3万 USD | 1.06億 USD | 7124.6万 USD | 4894.3万 USD |
| 販売・一般管理 | 2298.7万 USD | 2829.2万 USD | 2653.3万 USD | 2629.5万 USD | 2222万 USD |
| 営業費用 | 1.16億 USD | 1.28億 USD | 1.52億 USD | 9754.1万 USD | 7116.3万 USD |
| 受取利息 | 577.7万 USD | 1071.4万 USD | 997.8万 USD | 376万 USD | 9.1万 USD |
| 支払利息 | 3.6万 USD | 4000 USD | 2.5万 USD | 8万 USD | 17.6万 USD |
| 減価償却費と償却費 | 638.1万 USD | 646.8万 USD | 609.8万 USD | 266.7万 USD | 153.8万 USD |
| 営業利益 | −1.22億 USD | −1.28億 USD | −1.52億 USD | −7255.1万 USD | −6143.3万 USD |
| 純利益 | −1.17億 USD | −1.17億 USD | −1.43億 USD | −6979万 USD | −6199.9万 USD |
会社概要が更新されました 2026年10月10日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$27.00
上昇余地（381.28%）価格履歴は利用できません
最高：$27.00平均：$27.00最低：$27.00この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI211.61万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF86.05万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC13.02万0.01%13.17億 USD0.60%$183+0.11%
Dimensional - US Small Cap ETFDFAS10.69万0.00%338.69億 USD0.31%$78.35+0.32%
U.S. Micro Cap Portfolio ETFDFMC9.95万0.00%75.58億 USD0.43%$57.813+0.20%
Avantis U.S. Small Cap Equity ETFAVSC3.79万—30.61億 USD0.25%$69.98+0.03%
U.S. Vector Equity Portfolio ETF Class SharesDXUV2743.720.00%61.81億 USD0.26%$68.28+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
